Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$3.6 million.

  • Editas Medicine's Change in Account Payables fell 18397.13% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.3 million, marking a year-over-year decrease of 54025.48%. This contributed to the annual value of -$2.3 million for FY2024, which is 5321.72% down from last year.
  • As of Q3 2025, Editas Medicine's Change in Account Payables stood at -$3.6 million, which was down 18397.13% from $1.3 million recorded in Q2 2025.
  • Editas Medicine's 5-year Change in Account Payables high stood at $7.4 million for Q2 2024, and its period low was -$7.0 million during Q4 2024.
  • Over the past 5 years, Editas Medicine's median Change in Account Payables value was -$229000.0 (recorded in 2022), while the average stood at -$151526.3.
  • Its Change in Account Payables has fluctuated over the past 5 years, first plummeted by 19628.8% in 2023, then skyrocketed by 116194.56% in 2024.
  • Over the past 5 years, Editas Medicine's Change in Account Payables (Quarter) stood at $1.8 million in 2021, then skyrocketed by 46.49% to $2.7 million in 2022, then plummeted by 196.29% to -$2.6 million in 2023, then crashed by 169.81% to -$7.0 million in 2024, then soared by 49.12% to -$3.6 million in 2025.
  • Its last three reported values are -$3.6 million in Q3 2025, $1.3 million for Q2 2025, and -$27000.0 during Q1 2025.